Comparing the current results to its competitors, Zynex Inc reported Revenue decrease in the 3 quarter 2025 year on year by -73.26 %, despite the revenue increase by the most of its competitors of 18.21 %, recorded in the same quarter.
Zynex Inc 's Comment on Competition and Industry Peers
ZMS operates in the medical electrotherapy products market. Its principal competitors include International Rehabilitative Sciences, Inc. d/b/a RS Medical, EMSI, and H-Wave. The company also faces competition from providers of alternative medical therapies, including pharmaceutical and medical device companies.
March 25, 2025
In a striking turn of events, Zynex, Inc. (NASDAQ: ZYXI), a company that has garnered attention for its medical device innovations, now finds itself ensnared in legal turmoil. A class action lawsuit has been filed against the company, alleging serious wrongdoing that could shake the foundations of its financial credibility. On March 25, 2025, Holzer and Holzer, LLC announced the initiative, targeting investors who have suffered significant financial losses as a result of alleged misconduct by Zynex s leadership.Investors of Zynex, a company notable for its use of technology to enhance pain management and rehabilitation, are now grappling with disconcerting claims. The lawsuit contends that Zynex made materia...
Nevro Corp is a medical technology company that primarily focuses on developing and providing innovative solutions for chronic pain management. Their business model centers around the design, manufacturing, and commercialization of their proprietary spinal cord stimulation (SCS) systems. By leveraging advanced neuromodulation technology, they aim to improve the lives of patients suffering from debilitating chronic pain conditions.
Lensar Inc is a medical technology company that operates through a business model focused on the development and commercialization of advanced laser systems for ophthalmic procedures. They aim to provide innovative solutions to healthcare professionals in order to enhance precision, safety, and efficiency in eye surgeries.
Lucid Diagnostics Inc is a healthcare company that operates with a business model focused on developing and providing innovative diagnostic solutions for the early detection and prevention of diseases, aimed at improving patient outcomes and reducing healthcare costs. They leverage advanced technologies and medical expertise to deliver accurate and reliable diagnostic services to healthcare providers, enabling better decision-making and personalized treatment plans for patients.
Motus Gi Holdings Inc operates as a medical technology company that designs, develops, and commercializes innovative solutions for gastrointestinal endoscopy procedures. Their business model is centered around providing healthcare professionals with advanced imaging and therapeutic technologies to improve patient outcomes and enhance procedural efficiency.
NeuroMetrix Inc is a medical technology company that specializes in developing and selling wearable therapeutic devices and diagnostic products for chronic diseases and conditions. Their business model revolves around creating innovative solutions to improve patient outcomes and provide healthcare professionals with valuable insights.
Sources:
Zynex inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zynex inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
